Molecular secrets revealed: Antipsychotic docked in its receptor

January 31, 2018, National Institutes of Health
Widely-prescribed antipsychotic drug risperidone (purple) is shown interacting with its primary human brain target, the D2 dopamine receptor (green). Discovery of this molecular structure holds promise for rational design of more selective drugs, say researchers. Credit: Roth Lab, UNC

Antipsychotic drugs—which transformed mental health care following their chance discovery in the mid-20th Century—may finally be poised for a long-overdue makeover incorporating structure-based design. Scientists funded by the National Institutes of Health have achieved a landmark of psychiatric neuropharmacology: deciphering the molecular structure of a widely prescribed antipsychotic docked in its key receptor. They are hopeful that this discovery may hold secrets to designing better treatments for schizophrenia, bipolar disorder, and other mental illnesses.

"For the first time, we can understand precisely how atypical drugs bind to their primary molecular target in the human brain," explained Dr. Laurie Nadler, chief of the neuropharmacology program at the National Institute of Mental Health (NIMH), which co-funded the study along with the National Institute of General Medical Sciences and the National Cancer Institute. "This discovery opens the way for the rational design of a new generation of , hopefully with more desirable effects and fewer side effects."

Researchers Bryan Roth, M.D., Ph.D., of the University of North Carolina (UNC) Chapel Hill, Brian Shoichet, Ph.D., of the University of California San Francisco, and colleagues, report on their discovery of the crystal structure of the antipsychotic risperidone docked in the D2 dopamine receptor in the journal Nature.

Before becoming a laboratory scientist, psychiatrist Roth experienced first-hand the limitations of existing antipsychotics while treating patients with schizophrenia. The medications excel at quelling hallucinations and delusions, yet largely fail to address schizophrenia's debilitating cognitive and social impairments, while increasing risk for movement disorders, weight gain, and other metabolic and cardiovascular side effects.

Many of these side effects result from existing antipsychotics' interaction with several other types of in addition to the D2 receptor. Consequently, an in-depth understanding of the molecular workings holds hope for designing agents with just the desired properties that would act more precisely. For example, Roth and colleagues in 2016 reported developing such a designer pain-reliever that works via a key opioid receptor, but in a way that avoids morphine's side effects. Earlier this month, they similarly revealed a designer opioid compound that selectively acts through a different opioid receptor, that has a more benign side-effect profile.

The new molecular pictures show that risperidone binds to the D2 receptor in an unexpected way that could not be predicted based on previous structures of similar dopamine receptors. Notably, the D2 receptor harbors an unexpectedly deep "pocket" that the researchers think could be targeted to design more selective drugs with fewer side effects.

Explore further: Research revealed the first-ever crystal structure of the dopamine 2 receptor bound to an antipsychotic drug

More information: Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL. Nature. 2018 Jan 24, DOI: 10.1038/nature25758

Related Stories

Scientists take a big step toward building a better opioid

January 4, 2018

For the first time, scientists at the University of North Carolina School of Medicine and collaborators solved the crystal structure of the activated kappa opioid receptor bound to a morphine derivative. They then created ...

Investigators eye new target for treating movement disorders

January 19, 2018

Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson's disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Recommended for you

The perfect shot of espresso every time with chemistry

March 21, 2018

The average American drinks more than three cups of coffee a day, contributing to a $40 billion industry in the U.S. alone, according to the National Coffee Association. But not all coffee is created equal; flavor profiles ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.